[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"status-days":3,"theme-cdmo-generics":32},[4,18],{"date":5,"taiex_close":6,"taiex_chg":7,"taiex_chg_pct":8,"advancers":9,"decliners":10,"unchanged":11,"stocks":12,"turnover_sum":13,"margin_balance":14,"margin_chg":15,"short_balance":16,"short_chg":17},"2026-10-12",49301.96,-11.480000000003201,-0.00023279657634922568,868,916,158,1971,1044705369816,9174215,2895,175930,1165,{"date":19,"taiex_close":20,"taiex_chg":21,"taiex_chg_pct":22,"advancers":23,"decliners":24,"unchanged":25,"stocks":26,"turnover_sum":27,"margin_balance":28,"margin_chg":29,"short_balance":30,"short_chg":31},"2026-10-13",48341.31,-960.6500000000015,-0.019485026558781926,444,1337,161,1975,1306098703553,9070158,-104057,168869,-7061,{"id":33,"slug":34,"name":35,"category":36,"summary":39,"members":40,"ret_1d":41,"ret_5d":42,"ret_20d":43,"ret_60d":44,"up":45,"down":46,"flat":47,"mcap":48,"turnover":49,"spark":50,"verified_at":110,"updated_at":111,"as_of":19,"description":112,"facts":113,"drivers":123,"trends":127,"index_base_date":131,"published_at":132,"segments":133,"upstream":288,"downstream":289,"changes":296,"chips":297},56,"cdmo-generics","CDMO 與學名藥",{"slug":37,"name":38},"biotech","生技醫療","原料藥、委託開發製造與學名藥，營收比新藥穩定、看產能與國際認證。",11,-0.010249642314885767,0.016884193927534374,0.024717207778391037,0.01612220310646495,2,9,0,222441163689.5,803668837,[51,52,53,54,55,56,53,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109],84.81,85.11,86.2,86.71,85.66,85.86,84.66,84.54,83.66,83.88,85.33,85.43,86.76,86.05,87.75,89.02,89.16,88.13,87.96,86.35,86.81,86.28,86.93,89.74,90.14,89.29,89.04,89.17,88.7,88.48,88,87.72,87.52,86.55,86.49,86.25,86.03,86.75,86.4,85.31,85.78,86.67,86.83,88.58,88.84,88.17,88.08,88.81,87.64,87.54,88.57,88.33,87.55,87.06,87.12,88.03,88.85,89.45,88.53,"2026-10-14","2026-10-14T04:39:47.967341+08:00","這個題材涵蓋藥品產業中偏製造的一段：上游原料藥廠供應活性成分，中游委託開發製造（CDMO）替藥廠開發與量產，學名藥廠在專利到期後推出同成分藥品。國際藥廠委外比例提高、供應鏈分散，讓通過歐美查廠的台廠接到更多訂單。",[114,117,120],{"label":115,"value":116},"商業模式","原料藥銷售、委託製造、學名藥銷售",{"label":118,"value":119},"關鍵門檻","歐美主管機關查廠、品質系統",{"label":121,"value":122},"觀察重點","產能利用率、國際訂單",[124,125,126],"國際藥廠委外生產比例提高","藥品供應鏈分散，減少對單一國家依賴","專利到期帶來學名藥機會",[128,129,130],"透過併購取得產品與產能","生物藥 CDMO 需求成長","學名藥價格競爭與健保藥價調整","2023-12-29","2026-10-14T04:39:48.312544+08:00",[134,180,210,282],{"id":135,"tier":136,"name":137,"description":138,"members":139},163,"upstream","原料藥","藥品的活性成分與中間體。",[140,156,168],{"code":141,"name":142,"role":143,"relevance":144,"note":145,"industry":146,"close":147,"chg_pct":148,"ret_5d":149,"ret_20d":150,"mcap":151,"turnover":152,"signals":153},"1789","神隆","leader","high","高活性原料藥","生技醫療業",19.4,-0.010204081632653295,0.048648648648648596,0.043010752688172005,15340340906.8,8210821,[154,155],"rev_yoy","foreign_buy_5d",{"code":157,"name":158,"role":159,"relevance":144,"note":160,"industry":146,"close":161,"chg_pct":162,"ret_5d":47,"ret_20d":163,"mcap":164,"turnover":165,"signals":166},"4119","旭富","niche","原料藥與中間體",54.3,-0.02513464991023362,-0.06217616580310892,6489318826.2,10329112,[154,167,155],"rev_yoy_3m",{"code":169,"name":170,"role":159,"relevance":144,"note":171,"industry":146,"close":172,"chg_pct":173,"ret_5d":174,"ret_20d":175,"mcap":176,"turnover":177,"signals":178},"4746","台耀","原料藥與委託製造",47.6,-0.011422637590861928,0.0052798310454065245,0.024757804090419944,5724183838.8,30275715,[154,167,179,155],"eps_yoy",{"id":181,"tier":182,"name":183,"description":184,"members":185},164,"midstream","委託開發製造","替藥廠開發配方與量產，含小分子與生物藥。",[186,198],{"code":187,"name":188,"role":143,"relevance":144,"note":189,"industry":146,"close":190,"chg_pct":191,"ret_5d":192,"ret_20d":193,"mcap":194,"turnover":195,"signals":196},"6472","保瑞","藥品委託製造與產品併購",420,-0.005917159763313529,-0.0011890606420926764,0.035758323057953234,53766090000,243896611,[154,167,155,197],"trust_buy_5d",{"code":199,"name":200,"role":159,"relevance":144,"note":201,"industry":146,"close":202,"chg_pct":203,"ret_5d":204,"ret_20d":205,"mcap":206,"turnover":207,"signals":208},"6589","台康生技","生物藥委託開發製造",49.35,-0.014970059880239472,-0.026627218934911268,0.030271398747390377,15154210470.000002,20856588,[154,167,179,155,209],"holders_up",{"id":211,"tier":182,"name":212,"description":213,"members":214},165,"學名藥與特殊學名藥","專利到期後的同成分藥品。",[215,226,238,249,260,272],{"code":216,"name":217,"role":143,"relevance":144,"note":218,"industry":146,"close":219,"chg_pct":220,"ret_5d":221,"ret_20d":222,"mcap":223,"turnover":224,"signals":225},"1795","美時","學名藥與抗癌藥",178,-0.02997275204359673,0.0028169014084507005,0.005649717514124131,48111673400,287439427,[154,167,155,197,209],{"code":227,"name":228,"role":159,"relevance":144,"note":229,"industry":146,"close":230,"chg_pct":231,"ret_5d":232,"ret_20d":233,"mcap":234,"turnover":235,"signals":236},"4105","東洋","癌症用藥與特殊學名藥",82.1,0.003667481662591676,0.04853128991060007,0.06072351421188604,20414165000,87267240,[154,167,179,155,237,209],"foreign_streak_3d",{"code":239,"name":240,"role":159,"relevance":144,"note":241,"industry":146,"close":242,"chg_pct":243,"ret_5d":244,"ret_20d":245,"mcap":246,"turnover":247,"signals":248},"3705","永信","學名藥",60.7,0.00830564784053145,0.07243816254416946,0.08392857142857135,16171875068.1,42305180,[154,167,179,155,237],{"code":250,"name":251,"role":159,"relevance":144,"note":252,"industry":146,"close":253,"chg_pct":254,"ret_5d":255,"ret_20d":256,"mcap":257,"turnover":258,"signals":259},"1720","生達","學名藥與保健品",57.2,-0.005217391304347729,0.02508960573476715,0.01598579040852588,11243557925.6,19191122,[154,167,179],{"code":261,"name":262,"role":159,"relevance":263,"note":264,"industry":146,"close":265,"chg_pct":266,"ret_5d":267,"ret_20d":268,"mcap":269,"turnover":270,"signals":271},"4123","晟德","mid","藥品與生技投資",30.9,-0.01748807631160576,0.0016207455429497752,0.01812191103789118,24906055080,45611069,[154,167,155],{"code":273,"name":274,"role":159,"relevance":263,"note":252,"industry":146,"close":275,"chg_pct":276,"ret_5d":277,"ret_20d":278,"mcap":279,"turnover":280,"signals":281},"3716","中化控股",34,-0.004392386530014503,0.008902077151335286,0.0014727540500736325,5119693174,8285952,[179],{"id":283,"tier":284,"name":285,"description":286,"members":287},166,"downstream","醫院、藥局與國際藥廠","用藥端與委託客戶。",[],[],[290],{"id":291,"slug":292,"name":293,"category":294,"ret_1d":295},55,"new-drugs","新藥研發",{"slug":37,"name":38},-0.025792561311777984,[],{"members":40,"foreign_buy_count":46,"trust_buy_count":45,"holders_up_count":298},3]